$53M equity financing led by LAV and ARCH to advance pipeline programs (beta-amyloid, LRRK2) and hire a CFO; separate $5M MJFF grant excluded.
- Amount
- $53M
- Announced
- 4 December 2025
- Lead
- LAV
- Other investors
- ARCH Venture Partners
- Use of funds
- $53M equity financing led by LAV and ARCH to advance pipeline programs (beta-amyloid, LRRK2) and hire a CFO; separate $5M MJFF grant excluded.
- Checked
- Announced by the company